AKT1 and cancer: Liu and colleagues also described that TRPM7 inhibition reduces intracellular Ca2+ levels and attenuates EMT, migration and invasion via PI3K/Akt inhibition [63], and its silencing impairs glycolysis and proliferation [64], suggesting TRPM7 as a valuable marker for ovarian metastasis and a possible therapeutic marker, as well as having been described as a potential prognostic marker for this cancer type [65,66].